Abbott Laboratories

Abbott Laboratories delivered a mixed fourth-quarter 2025 report, edging past earnings expectations while falling short on revenue, as strength in Medical Devices was offset by weakness elsewhere in the portfolio. Adjusted diluted EPS came in at $1.50, a hair above the $1.49 consensus estimate for a 0.67% beat and 12% year-over-year growth, but revenue of $11.46 billion trailed the $11.81 billion consensus by 2.94%, even as sales grew 4.4% from a year earlier. The standout driver was the Medical Devices segment, which posted 12.3% reported growth fueled by continuous glucose monitor sales hitting $2.00 billion in the quarter, a 15% year-over-year gain that underscores growing demand for CGM technology alongside diabetes drug therapies. Nutrition remained a drag, falling 8.9% on deliberate pricing moves management hopes will restore volumes through 2026 product launches. Abbott also announced a $21 billion deal to acquire Exact Sciences, targeting cancer diagnostics. Looking ahead, the company guided for 6.5% to 7.5% organic sales growth in 2026 and adjusted EPS of $5.55 to $5.80, and extended its <a href="https://247wallst.com/investing/2026/01/15/dividend-king-abbott-shows-why-52-consecutive-increases-werent-luck-with-strong-cash-flow-coverage/">54-year dividend growth streak</a> with its 408th consecutive quarterly payout.